



JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

- **Description** p.1
- **Impact Factor** p.1
- **Abstracting and Indexing** p.1
- **Editorial Board** p.1
- **Guide for Authors** p.4



ISSN: 2213-7165

DESCRIPTION

The **Journal of Global Antimicrobial Resistance (JGAR)** is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes. The Journal aims to track the resistance threat worldwide and to give a comprehensive view of how infectious disease experts are challenging the problem.

Featuring peer-reviewed and up to date research articles, reviews and short notes JGAR will cover the key topics relating to antimicrobial resistance in the fields of: resistance mechanisms and gene transfer; antibacterial, antiviral, antifungal and antiparasitic resistance; microbiological and clinical studies stewardship; resistance to disinfectants; microbicides; antimicrobial resistance testing detection and diagnostic; PK/PD and resistance surveillance studies of resistant pathogens affecting humans at the global level, isolated from different hosts and environments.

IMPACT FACTOR

2014: 1.086 © Thomson Reuters Journal Citation Reports 2015

ABSTRACTING AND INDEXING

ScienceDirect
Scopus

EDITORIAL BOARD

Editor-in-Chief

Stefania Stefani, University of Catania, Catania, Italy

Founding Editors

Ian Gould, Aberdeen Royal Infirmary, Aberdeen, UK

Wing-Hong Seto, Queen Mary Hospital, Hong Kong

Po-Ren Hsueh, National Taiwan University Hospital (NTUH), Taipei, Taiwan

Scientific Secretariat

Simona Purrello, University of Catania, Catania, Italy

Section Editors

- Guido Antonelli**, Sapienza Università di Roma, Roma, Italy
Antiviral Resistance
- Robert Bonomo**, Veterans Affairs Medical Center, Cleveland, Ohio, USA
Antibacterial Resistance
- Fabrizio Bruschi**, Università di Pisa, Pisa, Italy
Antiparasitic resistance
- Karen Bush**, Indiana University, Bloomington, Indiana, USA
Antibacterial Resistance
- Alessandra Carattoli**, Istituto Superiore di Sanità, Roma, Italy
Genetic of resistance
- Robert Yen-Hsu Chen**, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Antibacterial Resistance
- Daniela Cirillo**, San Raffaele Scientific Institute, Milano, Italy
Resistance in Mycobacterium Tuberculosis
- Teresa Coque**, Ramón y Cajal University Hospital, Madrid, Spain
Antibacterial Resistance
- George L. Daikos**, National and Kapodistrian University of Athens, Athens, Greece
Microbiological and Clinical Studies Stewardship
- Andrea Endimiani**, Universität Bern, Berna, Switzerland
Diagnostics
- Alexander W. Friedrich**, University Medical Center Groningen, Groningen, Netherlands
: antimicrobial resistance; bacteriology
- Ana C. Gales**, Universidade Federal de São Paulo, São Paulo, Brazil
Surveillance Studies and Policies
- Luca Guardabassi**, University of Copenhagen, Frederiksberg, Denmark
Drug Resistance in Animals and Food
- Jesus Guinea**, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Antifungal Resistance
- Peter M. Hawkey**, University of Birmingham, Birmingham, England, UK
Antibacterial Resistance
- Benjamin Howden**, University of Melbourne, Victoria, Australia
Antibacterial Resistance
- Charles Kelly**, King's College London, London, England, UK
Disinfectants and Microbicides
- Wen-Chien Ko**, National Cheng Kung University Hospital, Tainan, Taiwan
Microbiological and Clinical Studies Stewardship
- Marco Oggioni**, Policlinico Le Scotte, Siena, Italy
Disinfectants and Microbicides
- Lance R Peterson**, NorthShore University Health System, Evanston, Illinois, USA
Diagnostics
- Gianni Pozzi**, Università degli Studi di Siena, Siena, Italy
Genetic of resistance
- Camilla Rodrigues**, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India
Antibacterial Resistance
- Alex Soriano**, Hospital Clínic de Barcelona, Barcelona, Spain
Microbiological and Clinical Studies Stewardship
- Vincent H. Tam**, UH College of Pharmacy Texas, Houston, Texas, USA
PK/PD and Resistance
- Paul Anantharajah Tambyah**, National University of Singapore, Singapore, Singapore
Surveillance Studies and Policies
- Pierre Tattevin**, Hospital de Pontchaillou, Rennes Cedex, France
Microbiological and Clinical Studies Stewardship
- Athanassios Tsakris**, University of Athens, Athens, Greece
- Shahana Urooj Kazmi**, University of Karachi, Karachi, Pakistan
Surveillance Studies and Policies
- Fiona Walsh**, Maynooth University, Kildare, Ireland
Antibiotic Resistance in the Environment
- Timothy Walsh**, Cardiff Institute of Infection & Immunity, Cardiff, Wales, UK
Genetic of resistance
- Minggui Wang**, Fudan University, Shanghai, China
Microbiological and Clinical Studies Stewardship
- Yun F (Wayne) Wang**, Emory University School of Medicine, Atlanta, Georgia, USA

Diagnostics

Heiman Wertheim, National Hospital of Tropical Diseases, Hanoi, Viet Nam

Microbiological and Clinical Studies Stewardship

Henrik Westh, Hvidovre Hospital, Hvidovre, Denmark

Genome notes

Gerry Wright, McMaster University, West Hamilton, Ontario, Canada

Antibiotic resistance in the environment

Advisory Board

Nisheeth Agarwal, Translational Health Science and Technology Institute, Gurgaon (Haryana), India

Abhijit Bal, University Hospital Crosshouse, Microbiology, Kilmarnock, Scotland, UK

Matteo Bassetti, Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Clinica Malattie Infettive, Udine, Italy

Rafael Cantón, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Doo Ryeon Chung, Sungkyunkwan University School of Medicine, Samsung Medical Center, Dept of Internal Medicine, Seoul, South Korea

Geoffrey Coombs, Fiona Stanley Hospital, Department of Microbiology, Murdoch, Western Australia, Australia

Laurent Dortet, Hôpital de Bicêtre, Laboratoire de Bactériologie-Hygiène, LE KREMLIN-BICETRE, France

Silvano Esposito, Università degli Studi di Salerno, Dipartimento di Malattie Infettive, Salerno, Italy

Evangelos Giamarellos-Bourboulis, University General Hospital Attikon, Dept. of Internal Medicine, Athens, Greece

Hajo Grundmann, University Medical Centre Groningen, Department of Medical Microbiology, Groningen, Netherlands

Deniz Gur, University of Hacettepe, Faculty of Medicine, Ankara, Turkey

Li Yang Hsu, National University Health System (NUHS), Dept. of Medicine, Singapore, Singapore

Keith Klugman, Emory University, Rollins School of Public Health, Atlanta, Georgia, USA

S Kohno, Nagasaki University, Nagasaki, Japan

Kyungwon Lee, Yonsei University College of Medicine, Department of Laboratory Medicine, Seoul, South Korea

Gabriel Levy Hara, Hospital Carlos G Durand, Infectious Diseases Unit, Buenos Aires, Argentina

Victor KE Lim, International Medical University, Dept. of Medicine, Kuala Lumpur, Malaysia

Jodi A Lindsay, St. George's University of London, Department of Clinical Sciences, London, England, UK

David Chien Lye, Tan Tock Seng Hospital, Communicable Disease Centre and Institute of Infectious Diseases and Epidemiology, Singapore, Singapore

Fiona MacKenzie, Aberdeen Royal Infirmary, Dept. of Microbiology, Aberdeen, UK

Francesco Menichetti, Cisanello Hospital, Infectious Diseases Unit, Pisa, Italy

Graeme Nimmo, MBBS MSc MPH MD DLSHTM FRACP FASM, Royal Brisbane and Women's Hospital, Pathology Queensland Central Laboratory, Brisbane, Queensland, Australia

Laura Pagani, Università degli Studi di Pavia, Department of Clinical-Surgical, Diagnostic and Paediatric Sciences, Pavia, Italy

Annalisa Pantosti, Istituto Superiore di Sanità, Dept Infectious, Parasitic and Immuno-Mediated Diseases, Roma, Italy

Federico Pea, SM Misericordia University Hospital of Udine, Institute of Clinical Pharmacology, Udine, Italy

Carlo-Federico Perno, Università di Roma "Tor Vergata", Dept. of Experimental Medicine and Surgery, Rome, Italy

Gunturu Revathi, The Aga Khan University Hospital, Dept of Pathology and Microbiology, Nairobi, Kenya

Gianmaria Rossolini, Università degli Studi di Siena, Policlinico Santa Maria alle Scotte, Siena, Italy

Ethan Rubinstein, University of Manitoba, Section of Infectious Diseases, Winnipeg, Manitoba, Canada

Raphael Saginur, Ottawa Hospital, Civic Campus, Ottawa, Ontario, Canada

Harald Seifert, Universität zu Köln, Institute for Medical Microbiology, Immunology and Hygiene, Köln, Germany

Robert Skov, Staten Serum Institut (SSI), Dept. of Microbiology & Infection Control, Copenhagen, Denmark

Kazuhiro Tateda, Toho University School of Medicine, Dept of Microbiology and Infectious Diseases, Tokyo, Japan

Fred C Tenover, Cepheid, Scientific Affairs, Sunnyvale, California, USA

Pietro Varaldo, Polytechnic University of Marche Medical School, Department of Biomedical Sciences and Public Health, Ancona, Italy

Claudio Viscoli, University of Genova, Division of Infectious Diseases, Genova, Italy

Erika Vlieghe, Institute of Tropical Medicine, Antwerp, Belgium

Hui Wang, Peking University People's Hospital, Department of Clinical Laboratories, Beijing, China

Jiunn-Jong Wu, National Cheng-Kung University, Department of Medical Laboratory Science and Biotechnology, Tainan, Taiwan

GUIDE FOR AUTHORS

These guidelines generally follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals". The complete document appears at <http://www.icmje.org>.

Types of paper

The following types of manuscripts are routinely accepted (please note that word count is from abstract to references but excluding references):

Original Articles: The form of these articles is discussed fully below; an abstract is required. They should be no longer than 4000 words and 40 references (as above, please note that word count also excludes tables, figures and legends). JGAR will be happy to consider papers of veterinary origin as long as there is some linkage of the scientific work back to human antibiotic use.

Letters: Headings should not be used in a letter; no abstract or keywords are required. The text should be no more than 800 words; there should be a maximum of 5 references and one table or figure may be included.

Reviews: An abstract and keywords are required. The text should be divided into sections by suitable headings. Tables and figures may be used as appropriate for the text. They should be no longer than 5000 words.

Short Communications: These should be no more than 2,000 words, with up to 20 references and a maximum of 3 figures or tables.

Hot topics: These tend to be invited papers but unsolicited Hot topics are welcome. There are no abstract, keywords or section headings.

Genome note: Should be no more than 800 words; there should be a maximum of 5 references and one table or figure may be included. A Genome note must state why the genome is of general interest and report on important or novel resistance or virulence mechanisms and if possible present the genome's MLST or a similar molecular unambiguous typing method.

Contact details for submission

If you have any problems submitting your paper through this system, please contact the Editorial Office on: e-mail: jgar@elsevier.com; tel: +44 (0)1865 843270; fax: +44 (0)1865 843992.

BEFORE YOU BEGIN

Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see <https://www.elsevier.com/publishingethics> and <https://www.elsevier.com/journal-authors/ethics>.

Human and animal rights

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans, <http://www.wma.net/en/30publications/10policies/b3/index.html>; Uniform Requirements for manuscripts submitted to Biomedical journals, <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. **All animal studies need to ensure they comply with the ARRIVE guidelines.** More information can be found at <http://www.nc3rs.org.uk/page.asp?id=1357>.

Conflict of Interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/

registrations, and grants or other funding. Please complete and upload this form ([pdf version](#) or [word version](#)) to declare funding, conflict of interest and to indicate whether ethical approval was sought. This information must also be inserted into your manuscript under the acknowledgements section with the headings below. If you have no declaration to make please insert the following statements into your manuscript:

Funding: None

Competing interests: None declared

Ethical approval: Not required

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <https://www.elsevier.com/sharingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <https://www.elsevier.com/editors/plagdetect>.

Contributors

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Changes to authorship

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Clinical trial results

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on <http://www.consort-statement.org>.

Registration of clinical trials

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, <http://www.icmje.org>) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <https://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <https://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <https://www.elsevier.com/permissions>.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <https://www.elsevier.com/OAauthoragreement>). Permitted third party reuse of open access articles is determined by the author's choice of user license (see <https://www.elsevier.com/openaccesslicenses>).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. For more information see <https://www.elsevier.com/copyright>.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some authors may also be reimbursed for associated publication fees. To learn more about existing agreements please visit <https://www.elsevier.com/fundingbodies>.

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

Open access

This journal offers authors a choice in publishing their research:

Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or on their behalf e.g. by their research funder or institution

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs (<https://www.elsevier.com/access>).

- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 2500**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information (<http://elsevier.com/greenopenaccess>). Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form.

This journal has an embargo period of 12 months.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the *Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals*, <https://www.elsevier.com/patient-consent-policy>. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via <http://ees.elsevier.com/jgar/default.asp>.

Referees

It is required that Authors provide a list of 4 or 5 potential reviewers (e-mail and phone number) who are knowledgeable in the subject matter, have no conflict of interest, and are likely to agree to review the manuscript. Please ensure that 2 of the potential reviewers are from a different country to the authors.

Editorial Review

All manuscripts are subject to peer review. If changes are requested, revisions received later than 3 months after this request will be treated as new submissions.

Authors in Japan please note: If you would like information about how to have the English of your paper checked, corrected and improved (before submission), please contact our Tokyo office who will inform you of the services provided by language correctors: Elsevier Japan, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo, 106 Japan, Tokyo; Tel: +81-3-5561-5032; Fax: +81-3-5561-5032.

PREPARATION

Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <https://www.elsevier.com/guidepublication>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Manuscripts

Please type all pages with double spacing and wide margins on one side of the paper. Title page, abstract, tables, legends to figures and reference list should each be provided on separate pages of the manuscript.

Use a true type font such as Times New Roman or Arial. The text should be in single-column format. Number the pages. In order to help our reviewers please number each line of the manuscript. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. Do not embed 'graphically designed' equations or tables, but prepare these using the facility in Word or as a separate file in Excel. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. Do not prepare tables in Powerpoint. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also: <http://www.elsevier.com/authors>). Do not import the figures into the text file but, instead, indicate their approximate locations directly in the electronic text and on the manuscript. See also the section on illustrations.

To avoid unnecessary errors you are strongly advised to use the spellchecker.

The title page should include: the title, the name(s) and affiliation(s) of the author(s), an address for correspondence, and telephone/fax numbers for editorial queries. All articles should include a Structured Abstract, i.e., Objectives, Methods, Results, Conclusions (maximum length 250 words) and 3-6 key words for abstracting and indexing purposes.

Please **do not split** the article into separate files (title page as one file, text as another, etc.). Ensure that the letter 'l' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your computer (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your computer to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the standard format for the program you are using. If your computer features the option to save files 'in flat ASCII', please do not use it.

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Italics are not to be used for expressions of Latin origin, for example, *in vivo*, *et al.*, *per se*. Use decimal points (not commas); use a space for thousands (10 000 and above). Provide the following data in your submission (in the order given). This is required for all types of paper submitted.

Article structure

Subdivision - numbered sections

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required (maximum length 250 words). The abstract must have a structured format, i.e., Objectives, Methods, Results, Conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. Do not cite references in the abstract. Non-standard or uncommon abbreviations should be avoided in the abstract, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See <https://www.elsevier.com/graphicalabstracts> for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: [Illustration Service](#).

Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <https://www.elsevier.com/highlights> for examples.

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

DNA sequences and GenBank Accession numbers

Many Elsevier journals cite 'gene accession numbers' in their running text and footnotes. Gene accession numbers refer to genes or DNA sequences about which further information can be found in the databases at the National Center for Biotechnical Information (NCBI) at the National Library of Medicine. Elsevier authors wishing to enable other scientists to use the accession numbers cited in their papers via links to these sources, should type this information in the following manner:

For each and every accession number cited in an article, authors should type the accession number in **bold, underlined text**. Letters in the accession number should always be capitalised. (See example below.) This combination of letters and format will enable Elsevier's typesetters to recognise the relevant texts as accession numbers and add the required link to GenBank's sequences.

Example: GenBank accession nos. **AI631510** , **AI631511** , **AI632198** , and **BF223228**), a B-cell tumour from a chronic lymphatic leukaemia (GenBank accession no. **BE675048**), and a T-cell lymphoma (GenBank accession no. **AA361117**).

Authors are encouraged to check accession numbers used very carefully. **An error in a letter or number can result in a dead link.** In the final version of the **printed article**, the accession number text will not appear bold or underlined. In the final version of the **electronic copy**, the accession number text will be linked to the appropriate source in the NCBI databases enabling readers to go directly to that source from the article.

Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork

Photographs should be presented as high quality jpg (jpeg) or tiff files with high contrast. Magnification should be indicated by a line representing the actual scale of reproduction (0.1 mm, 1mm or 10 mm); the use of magnification factors is to be avoided where possible. Illustrations will not be redrawn by

the Publisher: line figures should be suitable for direct reproduction. They should be prepared with black on white background, or be black-and-white images; they should be completely and consistently lettered, the size of the lettering being appropriate to that of the illustration, taking into account the necessary reduction in size.

Illustrations should be designed to fit either a single column (84 mm wide) or the full text width (175mm). However, if specifically requested by the author(s), plates may be reproduced larger than the typeset area; all originals for these should have the same proportions to achieve uniformity in their presentation. N.B. When plates are required to fill the entire page, the originals should have the dimensions 215 x 285 mm and contain no essential information or labelling near the edges. Further information about artwork can be found on the World Wide Web: access under <http://www.elsevier.com/locate/authorartwork>

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website:

<https://www.elsevier.com/artworkinstructions>.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see <https://www.elsevier.com/artworkinstructions>.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles (<http://citationstyles.org>), such as Mendeley (<http://www.mendeley.com/features/reference-manager>) and Zotero (<https://www.zotero.org/>), as well as EndNote (<http://endnote.com/downloads/styles>). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/journal-of-global-antimicrobial-resistance>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference style

References should be numbered consecutively (with parentheses) as they appear in the text. Type the reference list with double spacing on a separate sheet. References should accord with the system used in Uniform requirements for manuscripts submitted to biomedical journals (N Engl J Med 1991;324:424-428).

Examples:

- 1 Taylor DN, Sanchez JL, Candler W et al. Treatment of traveller's diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. *Ann Intern Med* 1991;114:731-734.
- 2 Mackowiak PA, ed. *Fever. Basic Mechanisms and Management*. New York: Raven Press, 1991.
- 3 Rubin M, Pizzo PA. Monotherapy in neutropenic cancer patients. In: Peterson PK, Verhoef J, eds. *Antimicrobial Agents Annual 3*. Amsterdam: Elsevier, 1988.

Please note that all authors should be listed when six or less; when seven or more, list only the first six and add 'et al.'. Do not include references to personal communications, unpublished data or manuscripts either 'in preparation' or 'submitted for publication'. If essential, such material may be incorporated into the appropriate place in the text. Recheck references in the text against reference list after your manuscript has been revised.

Journal abbreviations source

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <https://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <https://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Supplementary material

Supplementary material can support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Please note that such items are published online exactly as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel file or as a PowerPoint slide will appear as such online). Please submit the material together with the article and supply a concise and descriptive caption for each file. If you wish to make any changes to supplementary data during any stage of the process, then please make sure to provide an updated file, and do not annotate any corrections on a previous version. Please also make sure to switch off the 'Track Changes' option in any Microsoft Office files as these will appear in the published supplementary file(s). For more detailed instructions please visit our artwork instruction pages at <https://www.elsevier.com/artworkinstructions>.

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'

- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.

For any further information please visit our customer support site at <http://support.elsevier.com>.

AFTER ACCEPTANCE

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Once a paper has been accepted, the only changes possible are in relation to any queries raised by the Technical Editor or Typesetter.

Offprints

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](http://www.sciencedirect.com). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

AUTHOR INQUIRIES

You can track your submitted article at <https://www.elsevier.com/track-submission>. You can track your accepted article at <https://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>